Business Context and Reporting Period
This Form 8-K reports on the 2014 Annual Meeting of Stockholders held by TherapeuticsMD, Inc. on June 5, 2014. The filing details the voting results for director elections, executive compensation, and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes
No material financial changes are reported in this filing. The document confirms the successful adoption of three proposals by the stockholders:
- Election of nine directors to serve until the next annual meeting.
- Approval of a non-binding advisory vote on executive compensation for fiscal 2013.
- Ratification of Rosenberg Rich Baker Berman & Company as the independent auditor for the fiscal year ending December 31, 2014.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, risk factors, or discussion of unusual items. It serves strictly as a disclosure of the final voting results from the Annual Meeting.
Investor Verification Checklist
- Director Tenure: Verify the terms of the nine elected directors (Tommy G. Thompson, Robert G. Finizio, John C.K. Milligan, IV, Brian Bernick, M.D., Cooper C. Collins, Randall Stanicky, Robert V. LaPenta, Jr., Jules A. Musing, and Nicholas Segal).
- Auditor Appointment: Confirm the engagement of Rosenberg Rich Baker Berman & Company for the 2014 fiscal year.
- Compensation Vote: Note that the executive compensation vote for fiscal 2013 was non-binding advisory.
- Voting Support: Review the high level of support for all proposals, with Proposal 3 (Auditor Ratification) receiving over 122 million votes in favor.